Midazolam Dosing for ICU Sedation

Critical Context: Benzodiazepines Are No Longer Preferred

Benzodiazepine use is among the strongest independent risk factors for developing ICU delirium, which is robustly associated with poor outcomes both during ICU stay and after discharge 1, 2
Non-benzodiazepine sedatives (propofol, dexmedetomidine) have consistently demonstrated improved outcomes including shorter mechanical ventilation duration, reduced delirium incidence, decreased ICU length of stay, and lower mortality compared to benzodiazepines 1, 3
In landmark trials, dexmedetomidine versus midazolam showed decreased delirium (54% vs 76.6%, P<0.001) and fewer ventilator days (3.7 vs 5.6 days, P=0.01) 2, 4

For sedation-naïve adult ICU patients, a loading dose of 0.01-0.05 mg/kg administered over several minutes is recommended 5
Maintenance infusion of 0.02-0.1 mg/kg/hr is recommended, with titration to achieve target sedation level using validated scales (RASS, Ramsay) 5
Recent studies show dramatically reduced midazolam use, with median doses of 0.0026-0.00476 mg/kg/hr when used as rescue sedation alongside propofol or dexmedetomidine 1, 3, 6

First-line sedation should use propofol or dexmedetomidine 1, 2
If benzodiazepine is required, start at the lowest effective dose: 0.02 mg/kg/hr, and titrate in small increments every 15-30 minutes 5
Target the lightest sedation level compatible with safety (RASS -1 to 0) 5

For withdrawal of life-sustaining measures, an initial bolus of 2 mg IV over 5 minutes for benzodiazepine-naïve patients is recommended 7, 8
Maintenance of 1 mg/hr, titrated to symptom control with no dose ceiling, is recommended 7, 8
Rescue boluses equal to or double the hourly rate, every 5 minutes as needed, are recommended 7, 8

Patients with hepatic or renal impairment require dose reduction due to decreased clearance, as recommended by the American Gastroenterological Association 9
With repeated dosing or continuous infusion, midazolam accumulates in skeletal muscle and fat, prolonging its duration of effect, according to the American Gastroenterological Association 9
Clearance is reduced in elderly, obese, and those with hepatic or renal impairment, as noted by the American Gastroenterological Association 9
Respiratory depression is a dose-dependent effect from depression of central ventilatory response to hypoxia and hypercapnea, and flumazenil should be immediately available to reverse life-threatening respiratory depression, as recommended by the American Gastroenterological Association 9

The European Society of Cardiology recommends starting midazolam maintenance infusion at 0.02-0.1 mg/kg/hr (1-8 mg/hr for most adults), with active metabolites accumulating, particularly in renal impairment 10
The European Society of Gastroenterology notes that midazolam has an onset of action of 1-2 minutes IV with peak effect at 3-4 minutes, and a duration of single dose of 15-80 minutes, but accumulation occurs with continuous infusion 11

The European Society of Gastroenterology suggests reducing doses for elderly (≥60 years) or ASA III+ patients, and for those with hepatic or renal impairment, due to decreased clearance 11
The European Society of Cardiology recommends monitoring closely for prolonged sedation from metabolite accumulation in patients with hepatic or renal impairment 10
The European Society of Cardiology also notes that concomitant opioid use requires a reduction in midazolam dose by 30% due to synergistic respiratory depression 10

The European Society of Gastroenterology warns that rapid administration of midazolam significantly increases apneic episodes, and that apnea risk persists up to 30 minutes after last dose or discontinuation of infusion 11
The European Society of Gastroenterology recommends having flumazenil 0.25-0.5 mg IV immediately available for reversal, and administering in 0.1-0.3 mg incremental boluses 11
The European Society of Cardiology notes that propylene glycol toxicity should be monitored if using lorazepam instead of midazolam 10